The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1683
August 21, 2023
View Complete Issue         Table of Contents 2019 
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
August 21, 2023 (Issue: 1683)
Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now received full approval from the FDA based...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
Article code: 1683a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.